NeuroImmunology
Welcome to the new BÜHLMANN GanglioCombi® product group: the new, routine friendly package of commonly standardised, anti-ganglioside ELISA assays; different formats of assays for any type of laboratory for different requests.
The BÜHLMANN GanglioCombi® ELISA product group offers a choice of different, quantitative anti-ganglioside assays in different formats so meet the request for both small- to large-sized laboratories and neurologists. All assays of this product group have a common standardisation thus allowing inter-assay and inter-laboratory comparability. Each of these assays includes a defined Clibrator - as well as 3 controls of different titers. Results are expressed as %ratio.
The formats of this product group include:
The BÜHLMANN GanglioCombi® ELISA product group offers a choice of different, quantitative anti-ganglioside assays in different formats so meet the request for both small- to large-sized laboratories and neurologists. All assays of this product group have a common standardisation thus allowing inter-assay and inter-laboratory comparability. Each of these assays includes a defined Calibrator - as well as 3 controls of different titers. Results are expressed as %ratio.The formats of this product group include:
- BÜHLMANN GanglioCombi®-Light ELISA; combining on one Microtiter plate the clinically most relevant gangliosides, GD1b, GQ1b and GM1, inclusive individual IgG and IgM conjugate.
- BÜHLMANN GanglioCombi® ELISA. Both versions of GanglioCombi® offer a selection of the 6 six clinically most relevant gangliosides: GM1, asialo-GM1 (GA1), GM2, GD1a, GD1b and GQ1b and the GanglioCombi is equipped with one Microtiter plate and an IgG/ Mix conjugat.
- GanglioCombi-GM version is equipped with 2 Microtiter plates and one individual conjugate of each, IgG and IgM.
- Anti-GM1 ELISA allows analysing the most frequent anti-ganglioside antibody with IgG and/or IgM conjugate.
In addition to the new BÜHLMANN GanglioCombi ELISA® product group, the neuroimmunology portfolio contains a very sensitive and specific anti-MAG and anti-SGPG antibody assays. The anti-Interferon-ß BAB ELISA is the only commercial ELISA assay for anti-interferon ß antibody screening.
Common features:
Standardisation: Any of the tests contains a Calibrator from defined material as well as 3 Controls: medium, low and negative. The alignment of Calibrator and Controls in any of the “Combi (GanglioCombi, GanglioCombi-GM and GanglioCombi-Light)” assays should be done as follows:

As to the anti-GM1 ELISA assay there are several options:

Clinically evaluated cut-off based on an internal study consisting of a large number of N=200 normal blood donors (putative healthy blood donors, clinically not clarified) as well as a significant number of N=279 clinically defined serum samples we suggest a clinically evaluated cut-off at a %ratio of 50%.
The new cut-off value is combined with a quantisation of %ratio (titer) categories which are based on the same study data so to facilitate interpretation of results for clinicians.

| DOWNLOADS | ||||
Clinical Information |
Literarture List |
|||
English |
[PDF 0.3MB] | [PDF 0.3MB] | ||
Deutsch |
[PDF 0.3MB] | - | ||
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
Your local distributor
Order
About us
Job opportunities
Search
News
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
New Seegene DPO Movie showing how this unique and proprietary technology is working to allow innovative multiplexing.
The unique and proprietary DPO™(Dual-Priming-Oligonucleotide) technology is the corner stone for all of the Seegene products, and it is the key to achieve more
New EntroGen BRAF test (V600E/K/D) for the detection of important mutations found in melanoma on your real-time PCR instrument.
EntroGen has a new BRAF test that detects, beside the V600E mutation, also the V600K and the V600D, which are important mutations found in melanoma. more
BÜHLMANN innovations and news at the JIB
At the JIB Congress in Paris, 8th – 10th November 2011, BÜHLMANN presents the MDx products of EntroGen and AutoGenomics as well as new developments of its more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |
